Chimerix, Inc.

CMRX Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
CMRX Income Statement
CMRX Balance Sheet
CMRX Cash Flow
Congress Trading

Recent trades of CMRX by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
CMRX Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
CMRX Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
CMRX Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by CMRX's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $20,000 Jan 19, 2023 Issue: None
  • $50,000 Oct 17, 2022 Issue: Health Issues
  • $50,000 Jul 19, 2022 Issue: Health Issues
  • $50,000 Apr 18, 2022 Issue: Health Issues
  • $50,000 Jan 14, 2022 Issue: Health Issues
  • $50,000 Oct 18, 2021 Issue: Health Issues
  • $50,000 Jul 19, 2021 Issue: Health Issues
  • $40,000 Apr 16, 2021 Issue: Health Issues
  • $50,000 Jan 15, 2021 Issue: Health Issues
  • $50,000 Oct 20, 2020 Issue: Health Issues
  • $50,000 Jul 17, 2020 Issue: Health Issues
  • $50,000 Apr 16, 2020 Issue: Health Issues
  • $50,000 Jan 17, 2020 Issue: Health Issues
  • $30,000 Oct 21, 2019 Issue: Health Issues
  • $20,000 Jul 22, 2019 Issue: Health Issues
  • $15,000 Jul 09, 2019 Issue: Health Issues
  • $10,000 Apr 19, 2019 Issue: Health Issues
  • $15,000 Apr 12, 2019 Issue: Health Issues
  • $30,000 Jan 19, 2019 Issue: Health Issues
  • $15,000 Jan 17, 2019 Issue: Health Issues
  • $30,000 Oct 22, 2018 Issue: Health Issues
  • $15,000 Oct 03, 2018 Issue: Health Issues
  • $10,000 Jul 31, 2018 Issue: Health Issues
  • $15,000 Jul 09, 2018 Issue: Health Issues
  • $15,000 Apr 12, 2018 Issue: Health Issues
  • $15,000 Jan 08, 2018 Issue: Health Issues
  • $15,000 Oct 19, 2017 Issue: Health Issues
  • $15,000 Jul 06, 2017 Issue: Health Issues
  • $15,000 Apr 05, 2017 Issue: Health Issues
  • $15,000 Jan 11, 2017 Issue: Health Issues
  • $15,000 Oct 24, 2016 Issue: Health Issues
  • $30,000 Jul 11, 2016 Issue: Health Issues
  • $30,000 Apr 19, 2016 Issue: Health Issues
  • $30,000 Jan 13, 2016 Issue: Health Issues
  • $30,000 Oct 22, 2015 Issue: Health Issues
  • $30,000 Jul 13, 2015 Issue: Health Issues
  • $30,000 Apr 20, 2015 Issue: Health Issues
  • $20,000 Jan 14, 2015 Issue: Health Issues
  • $30,000 Oct 18, 2013 Issue: Health Issues
  • $30,000 Jul 22, 2013 Issue: Health Issues
  • $30,000 Apr 22, 2013 Issue: Health Issues
  • $30,000 Jan 18, 2013 Issue: Health Issues
  • $50,000 Oct 22, 2012 Issue: Health Issues
  • $60,000 Jul 20, 2012 Issue: Health Issues
  • $30,000 Apr 16, 2012 Issue: Health Issues
  • $30,000 Jan 16, 2012 Issue: Health Issues
  • $30,000 Oct 17, 2011 Issue: Health Issues
  • $30,000 Jul 14, 2011 Issue: Health Issues
  • $30,000 Apr 18, 2011 Issue: Health Issues
  • $50,000 Jun 09, 2009 Issue: Homeland Security Health Issues
  • $50,000 Jan 17, 2009 Issue: Health Issues Homeland Security
  • $50,000 Oct 17, 2008 Issue: Homeland Security Health Issues
  • $50,000 Jul 19, 2008 Issue: Health Issues Homeland Security
  • $50,000 Apr 21, 2008 Issue: Health Issues Homeland Security
  • $100,000 Feb 14, 2008 Issue: Homeland Security Health Issues
  • $100,000 Aug 04, 2007 Issue: Medical/Disease Research/Clinical Labs
  • $100,000 Feb 14, 2007 Issue: Medical/Disease Research/Clinical Labs
  • $140,000 Aug 08, 2006 Issue: Medical/Disease Research/Clinical Labs
  • $140,000 Feb 07, 2006 Issue: Medical/Disease Research/Clinical Labs
  • $120,000 Aug 15, 2005 Issue: Medical/Disease Research/Clinical Labs
Corporate Lobbying

Estimated quarterly lobbying spending

U.S. Patents

New patents grants

  • Patent Title: Pyrrolopyrimidine nucleosides and analogs thereof May. 14, 2024
  • Patent Title: Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7h-pyrrolo[2,3-d]pyrimidine-5-carboxamide and uses thereof Sep. 07, 2021
  • Patent Title: Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof Jul. 20, 2021
  • Patent Title: Pyrrolopyrimidine nucleosides and analogs thereof Mar. 09, 2021
  • Patent Title: Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof Nov. 26, 2019
  • Patent Title: Pyrrolopyrimidine nucleosides and analogs thereof Sep. 10, 2019
  • Patent Title: Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof Oct. 30, 2018
  • Patent Title: Methods of treating retroviral infections and related dosage regimes May. 01, 2018
  • Patent Title: Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof Jan. 09, 2018
  • Patent Title: Nucleoside phosphonate salts Sep. 19, 2017
  • Patent Title: Pyrrolopyrimidine nucleosides and analogs thereof Jul. 18, 2017
  • Patent Title: Pyrrolopyrimidine nucleosides and analogs thereof Jul. 11, 2017
  • Patent Title: Methods of treating retroviral infections and related dosage regimes Jul. 04, 2017
  • Patent Title: Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof Jun. 21, 2016
  • Patent Title: Phosphonate ester derivatives and methods of synthesis thereof Apr. 05, 2016
  • Patent Title: Methods of treating retroviral infections and related dosage regimes Mar. 08, 2016
  • Patent Title: Nucleoside phosphonate salts Apr. 14, 2015
  • Patent Title: Methods of treating viral infections Mar. 31, 2015
  • Patent Title: Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof Feb. 24, 2015
  • Patent Title: Compounds, compositions and methods for the treatment of poxvirus infections Feb. 04, 2014
  • Patent Title: Compounds, compositions and methods for treating ocular conditions Dec. 24, 2013
  • Patent Title: Phosphonate ester derivatives and methods of synthesis thereof Oct. 29, 2013
  • Patent Title: Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates Aug. 09, 2011
  • Patent Title: Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates Jul. 06, 2010
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded from public contracts

WallStreetBets

Number of mentions of CMRX in WallStreetBets Daily Discussion

CMRX News

Recent insights relating to CMRX

CNBC Recommendations

Recent picks made for CMRX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CMRX

CMRX Top Shareholders
Shareholder
Shares Held
CMRX Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

CMRX Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view CMRX Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top